20 Top-selling Vaccines -- H1 2012

Tools

Data on the biggest-selling vaccines helps us understand what's driving growth in the vaccines industry, and which companies are behind the wheel. Thanks in part to the adult influenza market and vaccines such as Gardasil and Prevnar, the global vaccines market has enjoyed a decidedly solid boost in revenue. Ten years ago, the vaccine market sat at $5.7 billion, according to Kalorama Information. Now, that market has soared to $27 billion.

Much of the growth comes as a result of a focus on flu prevention and an acceptance of adult vaccines. A few new vaccines joining the roster help, too. Sales of adult vaccines are expected to increase at a compound annual rate of 10.3% from 2010 to 2015, Kalorama reports.

As H1 came to a close, FierceVaccines decided to take a look at which prophylactic vaccines flew off the shelves--and which companies made the sales. 

Big Pharma products predictably dominated the list. Merck ($MRK) and GlaxoSmithKline ($GSK) take the cake when it comes to selling vaccines; each had 6 vaccines in the top 20 sales. Yet Sanofi ($SNY) and Pfizer ($PFE) had multiple products, too. And Novartis ($NVS) and Emergent BioSolutions each made an appearance.

With information provided by EvaluatePharma, the list is in. Take a look. -- Alison Bryant  (email | Twitter)

Vaccine: Prevnar 13

H1 Sales: $1.847 billion

Company: Pfizer

Use: Pneumococcal infection

  

Vaccine: PENTAct-HIB

H1 Sales: $672 million

Company: Sanofi

Uses: Diphtheria, Pertussis/whooping cough; Tetanus; Polio; Haemophilus influenza type b

   

Vaccine: Gardasil

H1 Sales: $608 million

Company: Merck & Co.

Use: human papillomavirus (HPV)

 

Vaccine: Pediarix

H1 Sales: $535 million

Company: GlaxoSmithKline

Use: Diphtheria; Tetanus; Pertussis/whooping cough; Hepatitis B; Polio

 

Vaccine: Hepatitis Vaccine Franchise

H1 Sales: $500 million

Company: GlaxoSmithKline

Use: Hepatitis A; Hepatitis B

 

Vaccine: Celtura

H1 Sales: $441 million

Company: Novartis

Use: Swine flu

Vaccine: Varivax

H1 Sales: $392 million

Company: Merck & Co.

Use: Varicella virus

 

Vaccine: Cervarix

H1 Sales: $285 million

Company: GlaxoSmithKline

Use: HPV

 

Vaccine: RotaTeq

H1 Sales: $284 million

Company: Merck & Co.

Use: Rotaviral gastroenteritis

 

Vaccine: Synflorix

H1 Sales: $274 million

Company: GlaxoSmithKline

Use: Pneumococcal infection; Otitis media

 

Vaccine: Rotarix

H1 Sales: $266 million

Company: GlaxoSmithKline

Use: Rotaviral gastroenteritis

 

Vaccine: Zostavax

H1 Sales: $224 million

Company: Merck & Co.

Use: Shingles; Herpes

 

Vaccine: Prevnar

H1 Sales: $222 million

Company: Pfizer

Use: Pneumococcal infection; Otitis media

   

Vaccine: Fluzone/Vaxigrip

H1 Sales: $219 million

Company: Sanofi

Use: Influenza

   

Vaccine: Menactra

H1 Sales: $217 million

Company: Sanofi

Use: Meningitis

    

Vaccine: Pneumovax

H1 Sales: $213 million

Company: Merck & Co.

Use: Pneumococcal infection

 

Vaccine: Adacel

H1 Sales: $207 million

Company: Sanofi

Use: Diphtheria; Pertussis/whooping cough; Tetanus
 

   

Vaccine: MMR-II

H1 Sales: $180 million

Company: Merck & Co.

Use: Measles, Mumps, Rubella

 

Vaccine: Boostrix

H1 Sales: $165 million

Company: GlaxoSmithKline

Use: Diphtheria; Tetanus; Pertussis/whooping cough

Vaccine: Biothrax

H1 Sales: $88 million

Company: Emergent BioSolutions

Use: Anthrax